Deals
Valeant Working With Banks to Review Options: Reuters
- Drugmaker has previously said it may sell `non-core' assets
- Company has received inquiries, with Xifaxan a possible target
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. is working with investment banks to review options after receiving interest in a number of its businesses, Reuters reported Thursday.
The drugmaker has previously said that it might dispose of certain “non-core” assets as it seeks to pay down some of its $32 billion in debt and return to stable footing after a disastrous eight-month run that has seen its stock lose almost 90 percent of its value.